Eylea

Aflibercept

Neovascular (wet) age-related macular degeneration (AMD). Visual impairment due to diabetic macular oedema (DME). 40 mg/mL: Visual impairment due to macular oedema secondary to retinal vein occlusion (branch or central RVO); due to myopic choroidal neovascularisation (myopic CNV).

Intravitreal inj 40 mg/mL Adult Recommended dose: 2 mg (0.05 mL). Wet AMD Initially 1 inj mthly for 3 consecutive doses, then extend treatment interval to 2 mth. Based on physician's judgement, treatment interval may be maintained at 2 mth or further extended using treat-&-extend regimen w/ inj intervals increased in 2- or 4-wkly increments to maintain stable visual &/or anatomic outcomes. Macular oedema secondary to RVO (branch or central RVO) After initial inj, treatment is given mthly. Interval between 2 doses should not be shorter than 1 mth. Continue mthly treatment until max visual acuity is achieved &/or there are no signs of disease activity; ≥3 consecutive mthly inj may be needed. May continue treatment w/ treat-&-extend regimen, gradually increasing treatment intervals to maintain stable visual &/or anatomic outcomes. DME Initially 1 inj mthly for 5 consecutive doses, followed by 1 inj every 2 mth. Based on physician's judgement, treatment interval may be maintained at 2 mth or individualized w/ treat-&-extend regimen, increasing intervals by 2-wk increments to maintain stable visual &/or anatomic outcomes. Myopic CNV Single inj. May administer additional doses if visual &/or anatomic outcomes indicate that disease persists. Interval between 2 doses should not be shorter than 1 mth. 114.3 mg/mL Adult Recommended dose: 8 mg (0.07 mL). Wet AMD & DME Initially 1 inj per mth for 3 consecutive doses. Intervals may then be extended up to every 4 mth based on physician's judgement of visual &/or anatomic outcomes. Subsequently, intervals may be further extended up to 5 mth (eg, w/ treat-&-extend dosing regimen) while maintaining stable visual &/or anatomic outcomes. Shorten interval if visual &/or anatomic outcomes deteriorate. Shortest interval between 2 inj is 2 mth in the maintenance phase.

Hypersensitivity. Active or suspected ocular or periocular infection. Active severe intraocular inflammation.

Monitor for IOP elevation immediately following inj. Use a different scleral site for subsequent inj. Risk of endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear & iatrogenic traumatic cataract. Do not inj while IOP is ≥30 mmHg. Potential for immunogenicity. Reports of non-ocular haemorrhages & arterial thromboembolic events. Increased risk of systemic adverse events w/ bilateral treatment. W/hold treatment in cases of rhegmatogenous retinal detachment or stage 3 or 4 macular holes; retinal break; decreased best-corrected visual acuity of ≥30 letters compared w/ the last assessment of visual acuity; subretinal haemorrhage involving the centre of fovea, or if the size of haemorrhage is ≥50% of total lesion area. W/hold dose w/in the previous or next 28 days in the event of a performed or planned intraocular surgery. Caution in patients w/ history of stroke or transient ischaemic attacks or MI w/in the last 6 mth; patients w/ risk factors for retinal pigment epithelial tears. Limited data in diabetic patients w/ HbA1c >12% or w/ proliferative diabetic retinopathy; patients w/ active systemic infections or concurrent eye conditions (eg, retinal detachment or macular hole); diabetic patients w/ uncontrolled HTN. Minor influence on the ability to drive & use machines. Do not use during pregnancy unless potential benefit outweighs potential risk to the foetus. Not recommended during breast-feeding. No relevant use in childn & adolescents. 40 mg/mL: Not recommended in patients w/ clinical signs of irreversible ischaemic visual function loss. Limited data in patients w/ DME due to type I diabetes; myopic CNV patients who are non-Asian, who have previously undergone treatment, & w/ extrafoveal lesions. No available data on the concomitant use w/ other anti-VEGF medicinal products (systemic or ocular). Women of childbearing potential have to use effective contraception during treatment & for at least 3 mth after last inj. 114.3 mg/mL: Limited data available on the concomitant use w/ other anti-VEGF medicinal products (systemic or ocular). Women of childbearing potential have to use effective contraception during treatment & for at least 4 mth after last inj.

40 mg/mL: Reduced visual acuity, retinal/conjunctival haemorrhage, eye pain. Retinal pigment epithelial tear/detachment, retinal degeneration, vitreous haemorrhage, cataract (including cortical, nuclear, subcapsular), corneal erosion/abrasion, increased IOP, blurred vision, vitreous floaters/detachment, inj site pain/haemorrhage, foreign body sensation in eyes, increased lacrimation, eyelid oedema, punctate keratitis, conjunctival/ocular hyperaemia. 114.3 mg/mL: Hypersensitivity; cataract, increased IOP, vitreous floaters/detachment, vitreous/retinal/conjunctival haemorrhage, reduced visual acuity, eye pain, punctate keratitis, corneal abrasion.

40 mg/mL: No established safety profile w/ adjunctive use of verteporfin photodynamic therapy & Eylea.

Other Eye Preparations

S01LA05 - aflibercept ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.

P₁S₁S₃